Recently, eIF4E has been reported to be required for ASMC hypertrophy in asthma, and inhibiting the phosphorylation of eIF4E may present a new therapeutic option to limit inflammation and remodeling in asthmatic airways (Zhou et al., 2005; Seidel et al., 2016). The gene discussed is EIF4E; the disease is asthma.